Blood pressure response to conventional and low-dose enalapril in chronic renal failure

British Journal of Clinical Pharmacology

Volumn 55, Issue 2, 2003, Pages 139-146

  Elung Jensen, Thomas ^a,b   Heisterberg, Jens ^a   Kamper, Anne Lise ^c   Sonne, Jesper ^a   Strandgaard, Svend ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c NONE

Author keywords

Blood pressure; Chronic renal failure; Dose response relationship; Drug; Enalapril; Enalaprilat

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRILAT; FOSINOPRIL; FUROSEMIDE; HEMOGLOBIN; LISINOPRIL; LOSARTAN; METOPROLOL; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; PROTEIN; VASODILATOR AGENT;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG CLEARANCE; DRUG EXPOSURE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; LONG TERM CARE; MALE; NEUROPATHY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POTASSIUM; PROTEINURIA;

EID: 0037326759     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01764.x     Document Type: Article

References (26)

1. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-2446.
2. Guidelines subcommittee. 1999 World Health Organization - International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183.
3. Pisoni R, Ruggenenti P, Remuzzi G. Renoprotective therapy in patients with nondiabetic nephropathies. Drugs 2001; 61: 733-745.
4. Todd PA, Goa KL. Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 1992; 43: 346-381.
5. Elung-Jensen T, Heisterberg J, Kamper AL, Sonne J, Strandgaard S, Larsen NE. High serum enalaprilat in chronic renal failure. J Renin-Angiotensin-Aldosterone System 2001; 4: 240-245.
6. Lapinski R, Perico N, Remuzzi A, Sangalli F, Benigni A, Remuzzi G. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 1996; 7: 653-660.
7. Till AE, Gomez HJ, Hichens M et al. Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers. Biopharm Drug Dispos 1984; 5: 273-280.
8. Weisser K, Schloos J, Lehmann K, Dusing R, Vetter H, Mutschler E. Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects. Eur J Clin Pharmacol 1991; 40: 95-99.
9. Kampmann J, Siersbaek-Nielsen K, Kristensen M, Hansen JM. Rapid evaluation of creatinine clearance. Acta Med 1974; 196: 517-520.
10. Brøchner-Mortensen J. A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 1972; 30: 271-274.
11. Lundberg P-A, Lindstedt G, Andersson T, Branegård B, Lundquister G, Nyström E. Single-reagent microcentrifugal assay for angiotensin converting enzyme in serum. Clin Chem 1984; 30: 163-163.
12. Churg J, Cotran RS, Sinniah R, Sakaguchi H, Sobin L. Renal Disease: Classification and Atlas of Tubulo-Interstitial Diseases. Tokyo: Igaru-Shoin, 1985.
13. Riley LJ Jr, Fruncillo RJ, Smith R et al. Enalapril maleate in renal failure: relationships between blood pressure response, aldosterone and accumulation of active metabolite. Clin Res 1999; 33: 368A.
14. Hersh AD, Kelly JG, Laher MS, Carmody M, Doyle GD. Effect of hydrochlorothiazide on the pharmacokinetics of enalapril in hypertensive patients with varying renal function. J Cardiovasc Pharmacol 1996; 27: 7-11.
15. Peters H, Ritz E. Dosing angiotensin II blockers - beyond blood pressure. Nephrol Dial Transplant 1999; 14: 2568-2570.
16. Keilani T, Danesh FR, Schlueter WA, Molteni A, Batlle D. A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis 1999; 33: 450-457.
17. Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100: 2312-2318.
18. Biollaz J, Burnier M, Turini GA et al. Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther 1981; 29: 665-670.
19. Ferguson RK, Vlasses PH, Swanson BN et al. Effects of enalapril, a new converting enzyme inhibitor, in hypertension. Clin Pharmacol Ther 1982; 32: 48-53.
20. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I, Davies RO. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor 'MK-421'. Lancet 1981; 2: 543-547.
21. Karlberg BE, Fyhrquist F, Gronhagen-Riska C, Tikkanen I, Ohman KP. Enalapril and lisinopril in renovascular hypertension - antihypertensive and hormonal effects of two new angiotensin-converting-enzyme (ACE) inhibitors. A preliminary report. Scand J Urol Nephrol Suppl 1984; 79: 103-106.
22. Edeki T, Johnston A, Li-Kam WE, Turner P. Enalapril pharmacokinetics and ACE inhibition, following single and chronic oral dosing. Int J Clin Pharmacol Ther 1994; 32: 142-146.
23. Ajayi AA, Campbell BC, Kelman AW, Howie C, Meredith PA, Reid JL. Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril. Int J Clin Pharmacol Res 1985; 5: 419-427.
24. Kamper AL, Thomsen HS, Nielsen SL, Strandgaard S. Initial effect of enalapril on kidney function in patients with moderate to severe chronic nephropathy. Scand J Urol Nephrol 1990; 24: 69-73.
25. Kamper AL, Strandgaard S, Leyssac PP. Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 1992; 5: 423-430.
26. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 1998; 158: 26-32.